Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL).
Peter PickkersDerek C AngusKristie BassRinaldo BellomoErik van den BergJuliane BernholzMorten H BestleKent DoiChistopher J DoigRicard FerrerBruno FrancoisHenrik GammelagerUlf Goettrup PedersenEric HosteSusanne IversenMichael JoannidisJohn A KellumKathleen LiuMelanie MeerschRavindra MehtaScott MillingtonPatrick T MurrayAlistair NicholMarlies OstermannVille PettiläChristoffer SollingMatthias WinkelPaul J YoungAlexander Zarbocknull nullPublished in: Intensive care medicine (2024)
Among critically ill patients with SA-AKI, ilofotase alfa did not improve day 28 survival. There may, however, be reduced MAKE90 events. No safety concerns were identified.